Question

In: Operations Management

Case Analysis: Valeant Pharmaceuticals is a specialty drug manufacturer operating in the fast-cycle pharmaceutical industry. In...

Case Analysis:

Valeant Pharmaceuticals is a specialty drug manufacturer operating in the fast-cycle pharmaceutical industry. In this business, size often matters and Valeant, along with most of the major players in the industry, has aggressively utilized mergers and acquisitions to acquire R&D capabilities and other key strategic resources, create synergies, capture market share, and use acquired legacy products to support future growth. Valeant’s 2010 merger with Biovail Corp was designed with all of these benefits in mind. To develop an effective strategic position, Valeant must address several important external factors including the global economy, advances in technology, population demographics and sociocultural influences, and shifting political/legal forces that affect not only the drug approval process but also the changing nature of healthcare. To address these considerations, Valeant must develop strategies in the areas of marketing and sales, product innovation, operational speed and efficiency, and M&A to position itself for future success The purpose of this case study is to determine if the company’s recent merger with Biovail, other M&A’s and restructuring efforts will yield the benefits promised to shareholders and enable the firm to compete more effectively in the marketplace.To reasonably determine the merit of its strategic approach, external environmental trends, competitor positions, financial indicators, internal resources, and company strategies must be considered.The results of the analysis can then be used to suggest measures which can improve Valeant’s strategic position and potential for ongoing success.

Question: Examine trends in the general and industry environments that impact Valeant’s pharmaceutical business.What conditions are pertinent to the strategic decisions presently facing the company?

Solutions

Expert Solution

Trends in the general and industry environments that impact Valeant’s pharmaceutical business,

  • In this business, size often matters and Valeant, along with most of the major players in the industry, has aggressively utilized mergers and acquisitions to acquire R&D capabilities and
  • Other key strategic resources, create synergies, capture market share, and use acquired legacy products to support future growth.

Conditions that are pertinent to the strategic decisions presently facing the company, To develop an effective strategic position, Valeant must address several important external factors including the

  • Global economy,
  • Advances in technology,
  • Population demographics
  • Sociocultural influences,
  • Shifting political/legal forces that affect not only the drug approval process but also the changing nature of healthcare.
    To address these considerations, Valeant must develop strategies in the areas of-
  • Marketing and sales, product innovation, operational speed and efficiency, and
  • M&A to position itself for future success that will yield the benefits promised to shareholders and enable the firm to compete more effectively in the marketplace.
  • To reasonably determine the merit of its strategic approach, external environmental trends, competitor positions, financial indicators, internal resources, and company strategies must be considered.
  • The results of the analysis can then be used to suggest measures which can improve Valeant’s strategic position and potential for ongoing success.


Related Solutions

The variance in drug weights is critical in the pharmaceutical industry. For a specific drug, with...
The variance in drug weights is critical in the pharmaceutical industry. For a specific drug, with weights measured in grams, a sample of 20 units provided a sample variance of s^2 = 0.49. a)  construct a 90% confidence interval estimate for the population variance b) construct a 90% confidence interval estimate of the population standard deviation
If you represented an insurance company or competing pharmaceutical manufacturer, how would you respond to the drug price increases imposed by Turing Pharmaceuticals?
If you represented an insurance company or competing pharmaceutical manufacturer, how would you respond to the drug price increases imposed by Turing Pharmaceuticals? Given the absence of limitations on how much a company can charge for a given product, does the increase in the price of Daraprim create justification for the imposition of price controls at times? How does this intersect with the idea that a free-market economy dominates in America?
1. The variance in drug weights is critical in the pharmaceutical industry. For a specific drug,...
1. The variance in drug weights is critical in the pharmaceutical industry. For a specific drug, with weights measured in grams, a sample of 18 units provided a sample variance of s2 = 0.36. Construct a 90% confidence interval estimate of the population variance for the weight of this drug. Select one: a. 0.22 ≤≤ σσ2 ≤≤ 0.71 b. 0.42 ≤≤ σσ2 ≤≤ 0.87 c. 2.08 ≤≤ σσ2 ≤≤ 16.7 d. 1.23 ≤≤ σσ2 ≤≤ 2.55 2. A sample of...
4) Variance in drug weights is critical in the pharmaceutical industry. For a specific drug with...
4) Variance in drug weights is critical in the pharmaceutical industry. For a specific drug with weights measured in grams if the variance is greater than 0.28 the drug could be ineffective. A sample of 18 pills provided a sample variance of 0.36. (a) Is there evidence to say that the drug variance is too high to be effective with 95% confidence? (b) Construct a 90% confidence interval for the population variance.
1.The operating cycle of a manufacturer is longer and more complex than the operating cycle of...
1.The operating cycle of a manufacturer is longer and more complex than the operating cycle of a merchandiser. Select one: True False 2.The income statement shows cost of goods sold separately from other expenses. Select one: True False 3.Inventory shrinkage is unrecorded decreases in inventory due to breakage, shoplifting, and theft. Select one: True False 4. Sales returns and allowances is an expense account and reduces net income. Select one: True False 5.Which of the following businesses is likely to...
A pharmaceutical manufacturer has projected net profits for a new drug that is being released to...
A pharmaceutical manufacturer has projected net profits for a new drug that is being released to the market over the next five years: Year 1 2 3 4 5 Net Profit ($300,000,000) ($145,000,000) $50,000,000 $125,000,000 $530,000,000 A fixed cost of $80,000,000 has been incurred for research and development (in year 0). Use a spread-sheet to find the net present value of these cash flows for a discount rate of 3%. Explain steps pleace
Give an industry life-cycle analysis of Nestle.
Give an industry life-cycle analysis of Nestle.
Clement Corp., a pharmaceutical manufacturer, licensed a drug patent to Global Corp. for royalties of 5%...
Clement Corp., a pharmaceutical manufacturer, licensed a drug patent to Global Corp. for royalties of 5% of drug sales. Royalties are payable twice yearly on April 15 for sales from July through December of the previous year and on October 15 for January – June same-year sales. In year 8, Global paid royalties of $20,000 and $25,000 on April 15 and October 15, respectively. In response to Global’s estimate of July – December sales of the drug, Clement correctly recognized...
A pharmaceutical manufacturer wants to investigate the bioactivity of a new drug. A completely randomized single-factor...
A pharmaceutical manufacturer wants to investigate the bioactivity of a new drug. A completely randomized single-factor experiment was conducted with three dosage levels, and the following results were obtained. Use R to run ANOVA to test if the dosage has some effects or not. Dosage Observations 20g 24 28 37 30 30g 37 44 31 35 40g 42 47 52 38 a. Find the test statistic. b. Find the p-value (Please input a decimal value. Please input 0 or 0.0001...
Example 1 A pharmaceutical manufacturer does a chemical analysis to check the potency of products. The...
Example 1 A pharmaceutical manufacturer does a chemical analysis to check the potency of products. The standard release potency for cephalothin crystals is 910. An assay of 16 lots gives the following potency data: 897 914 913 906 916 918 905 921 918 906 895 893 908 906 907 901 Assume the population standard deviation is 8 units. Test the hypothesis that the population mean potency is different from the standard release potency. (1) Define the population quantity of interest...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT